Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 427 results for "mirati"

S-8 - Mirati Therapeutics, Inc. (0001576263) (Filer)

Document Format Files Seq Description Document Type Size 1 S-8 a15-13384_1s8.htm S-8 119786 2 EX-5.1 a15-13384_1ex5d1.htm EX-5.1 9361 3 EX-23.1 a15-13384_1ex23d1.htm EX-23.1 3046 4 EX-23.2 a15-13384_1ex23d2.htm EX-23.2 3444 Complete submission text ... SEC, 3 weeks ago

8 images for mirati

Ticker Report, 3 days ago
American Banking News, 2 weeks ago
American Banking News, 3 months ago
Mideast Time, 3 months ago
KXXV-TV, 3 months ago, 4 months ago
Nasdaq, 4 months ago
Pharmaceutical Business Review, 5 months ago
Ticker Report

Brean Downgrades Mirati Therapeutics To Hold

In a report published Monday, Brean Capital analyst Jonathan Aschoff downgraded the rating on Mirati Therapeutics, Inc (NASDAQ: MRTX) from Buy to Hold. Mirati's ASCO presentation described the first look of the 1050 mg dose expansion cohort, while ...
 Benzinga.com4 weeks ago Notable Downgrades: Mirati Therapeutics (MRTX), Juniper (JNPR), Cloud Peak Energy (CLD), Paylocity Holding (PCTY)  Wall Street Pit4 weeks ago Mirati Therapeutics Cut to Hold at Brean Capital (MRTX)  WKRB News4 weeks ago Mirati Therapeutics Stock Rating Lowered by Brean Capital (MRTX)  American Banking News4 weeks ago

Mirati Therapeutics drops after patients treated with MGCD265 do not meet RECIST criteria for clinical response

News Editor Thinly traded Mirati Therapeutics (MRTX -17.2%) slumps on a 7x surge in volume in response to the presentation of an abstract (#2589) at ASCO on a Phase 1 trial of its tyrosine kinase inhibitor, MGCD265, in heavily pretreated patients ...
 Seeking Alpha4 weeks ago

Morning Market Losers

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares dipped 24.44 percent to $27.70 after the company presented data from MGCD265 showing preliminary evidence of clinical efficacy at the ASCO. Brean Capital downgraded Mirati Therapeutics from Buy to ...
 Benzinga.com4 weeks ago Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015  News-Medical.Net4 weeks ago Mirati Therapeutics Release: Initial Data From Ongoing Expansion Study Of MGCD265 Show Preliminary Evidence Of Clinical Efficacy In Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients With MET Gene Alterations  BioSpace4 weeks ago Initial Data From Ongoing Expansion Study Of MGCD265 Show Preliminary Evidence Of Clinical Efficacy In Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients With MET Gene Alterations  TheStreet.com1 month ago

Mirati Therapeutics (MRTX) Shows Strength: Stock Up 7.2% - Tale of the Tape

Mirati Therapeutics, Inc. ( MRTX ) was a big mover last session, as the company saw its shares rise over 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend ...
 Yahoo! Finance1 month ago

Mirati Therapeutics misses by $0.13

To screen ETFs by asset class, performance, yield and more, check out the ETF Hub.
 Seeking Alpha1 month ago

Mirati reports 1Q loss

On a per-share basis, the San Diego-based company said it had a loss of 77 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks
 Yahoo! UK and Ireland1 month ago

Hamdan bin Zayed meets citizens miratis in Zayed City

Pictures Videos MADINAT ZAYED, Abu Dhabi, 22nd June 2015 (WAM) --- H.H. Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in the Western Region, today met with citizens at the majlis of the city. H.H. Sheikh Hamdan exchanged cordial ...
 WAM.ae1 week ago

Can The Uptrend Continue for Mirati Therapeutics (MRTX)?

These 7 were hand-picked from the list of 220 Zacks Rank #1 Strong Buys with earnings estimate revisions that are sweeping upward. Their stock prices are expected to rise sooner than the others. Today, this Special Report will be available to ...
 Zacks.com1 month ago
Ticker Report

Zacks Lowers Mirati Therapeutics to Sell (MRTX)

Mirati Therapeutics (NASDAQ:MRTX) was downgraded by Zacks from a hold rating to a sell rating in a research note issued on Friday. According to Zacks, Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel ...
 Ticker Report3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less